Venetoclax in Patients With CLL Relapsed/Refractory to Ibrutinib or Idelalisib

December 3-6, 2016; San Diego, California
Venetoclax associated with high response rates and durable responses in patients with CLL who progressed on ibrutinib, idelalisib, or both.
Format: Microsoft PowerPoint (.ppt)
File Size: 620 KB
Released: December 8, 2016

Acknowledgements

This activity is supported by educational grants from
Amgen
Celgene Corporation
Incyte
Merck & Co., Inc.
Seattle Genetics

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

Downloadable summary slideset of key takeaways from a live NCCN/CCO Webinar focused on current treatment in CLL/SLL.

Jeremy S. Abramson, MD, MMSc Anthony Mato, MD William G. Wierda, MD, PhD Released: June 15, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue